Last update March 25, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Cisapride is also known as
Cisapride in other languages or writings:
Cisapride belongs to this group or family:
Main tradenames from several countries containing Cisapride in its composition:
|Ped.Relat.Dose||0.1 - 0.2||%|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Cisapride, a substituted benzamide, is a prokinetic drug that increases gastrointestinal motility and accelerates gastric emptying. Used in gastroesophageal reflux. Oral administration
It is excreted into breast milk in clinically non-significant amount. (Hofmeyr 1986)
Cisapride may increase prolactin secretion, although less frequently than metoclopramide. (Fumagalli 1994)
American Academy of Pediatrics states that it is a medication usually compatible with breastfeeding. (AAP 2001)
Because of the high risk of QT-interval prolongation and cardiac arrhythmias in patients who are taking it, especially if other medicines are associated or patients are affected by other conditions, it has been withdrawn from the market in many countries. (MedlinePlus 2017, Mahadevan 2006, ONU 2005)
See below the information of this related product: